DOSAGE AND DURATION
Dosage of 20 mg to 80 mg daily in combination with interferon-beta therapy. Based on negative results in controlled trials, this use is not supported.
RESULTS
The use of adjunctive atorvastatin therapy (with interferon-beta) in the management of relapsingremitting MS has been evaluated in a limited number of controlled and noncontrolled trials enrolling approximately 200 patients and has demonstrated confl icting results. It showed moderate or no benefi t when compared to interferon therapy alone [4] [5] [6] [7] ; in one controlled trial, the combination therapy resulted in increased disease activity. 5 Two meta-analyses of statins (atorvastatin and simvastatin) examining the same trials found that there was no benefi t of statins in regard to MS relapse rates, disease progression, or change in disability scores. 8, 9 
Meta-analyses
A meta-analysis evaluating the effi cacy of statins in combination with interferon therapy for the management of patients with relapsing remitting MS identifi ed 4 unique randomized controlled trials. The evaluated statins included simvastatin and atorvastatin, with 2 studies each. Analysis did not reveal This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specifi c drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specifi c use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu. signifi cant benefi t associated with statin use compared to control groups in regard to relapse rates (relative risk [RR], 0.99; 95% CI, 0.53 to 1.85; I 2 = 54.1%), risk of disease progression (RR, 1.31; 95% CI, 0.73 to 2.36; I 2 = 38.1%), or change in Expanded Disability Status Scale (EDSS) scores from baseline (weighted mean difference, -0.06; 95% CI, -0.30 to 0.19; I 2 = 0%). 8 Another meta-analysis evaluated the same 4 controlled trials with the use of statins in the management of relapsing-remitting MS (2 with atorvastatin and 2 with simvastatin). Only 3 studies were considered to be of good methodological quality. The authors concluded that the evidence did not support the use of either atorvastatin or simvastatin for the reduction of MS relapses or prevention of disease progression. No serious adverse events were associated with statin use. 9
Controlled Trials
In a single-blinded (evaluator), parallel group, multicenter trial, 77 adult patients with relapsing-remitting MS received interferon beta-1b every other day for 3 months, after which they were randomized to continue interferon therapy alone or in combination with atorvastatin (40 mg daily) for an additional 12 months. Interferon dosing was initiated at 0.0625 mg every other day and increased weekly by 0.0625 to 0.25 mg every other day for the baseline period of 3 months.
The primary endpoint, the proportion of patients with new lesions on T2-weighted MRI images at 15 months compared to baseline (3 months), was not signifi cantly different between the combination therapy and interferon-alone groups (47.37% vs 39.47%). The odds ratio for the combination therapy group for the primary endpoint was 1.14 (95% CI, 0.366 to 3.56; P = .81). There were also no differences between the 2 treatment groups at 15 months for secondary endpoints, including mean number of new lesions or mean change in lesion volume on T2-weighted images, mean number of lesions on T1-weighted images, total brain volume, volume of grey or white matter, EDSS, multiple sclerosis functional composite (MSFC), relapse rates, time to fi rst relapse, and number of relapse-free patients. There were no signifi cant differences between the 2 groups for the total number of patients experiencing an adverse event or the type of adverse event, with the exception of elevated liver enzymes, which was signifi cantly higher in the combination group (23.1% vs 5.3%; P = .02). The authors concluded that the addition of atorvastatin 40 mg daily to interferon beta-1b in the management of relapsing-remitting MS did not demonstrate benefi t. 6 In a longitudinal controlled trial, 45 adult patients with relapsing-remitting MS who experienced at least one relapse or developed a gadolinium-enhanced lesion upon MRI during 12 months of therapy with subcutaneous interferon beta-1a (44 mcg 3 times a week) were randomized to continue interferon therapy alone or in combination with atorvastatin (20 mg daily) for 24 months. Primary outcome was brain MRIs to detect contrast enhance lesions (CELs) and were conducted at 12 and 24 months. Assessments included EDSS and laboratory parameters at baseline (after randomization), 1 month, and every 3 months for 24 months. When compared to baseline measurement, the number of CELs at the 24-month assessment was signifi cantly decreased in the combination group (1.3 vs 0.11; P = .007) but not in the interferon-only group (1.1 vs 0.6; P = .32), although the difference between the 2 groups was not signifi cant (P = .10). The mean number of relapses in the 24-month follow-up period was 0.5 and 1.6, respectively (P = .03). Although both groups experienced fewer relapses when compared to the 2-year period prior to randomization, this difference was only signifi cant for the combination therapy group. Mean EDSS scores were unchanged at fi nal assessment in the combination therapy group (2.8 vs 3.0; P = .80) and were increased in the placebo group (3.0 vs 3.4; P = .04); the difference between the 2 groups was not signifi cant (P = .60). Serum total cholesterol and low-density lipoprotein (LDL) levels were significantly decreased in the combination group, but there were no differences between the 2 therapies for other laboratory parameters (eg, liver enzymes, creatine phosphokinase [CPK]). The authors concluded that low-dose atorvastatin therapy may be benefi cial as add-on therapy in poor responders to monotherapy with interferon beta-1a. 7 In a double-blinded, placebo-controlled trial, 29 adult patients with relapsing-remitting MS received subcutaneous interferon beta-1a (44 mcg 3 times a week) and were selected for enrollment if they remained clinically stable over a 6-month period prior to study entry. Interferon therapy was continued throughout the trial. Patients were then randomized to receive concurrent therapy with atorvastatin (40 mg or 80 mg daily) or placebo for 6 months. Main outcome measurements, including clinical relapse, new lesions upon MRI, and MS-related disease activity via EDSS evaluations, were assessed at baseline, 3, 6, and 9 months after the initiation of therapy. Safety assessments (eg, transaminase levels, total cholesterol, CPK) were performed at baseline, monthly during treatment, and 3 months after the end of therapy. A total of 26 patients took at least one dose of the study drug and were included in the intent-to-treat analysis for atorvastatin 40 mg daily (n = 7), atorvastatin 80 mg daily (n = 10), and placebo (n = 9). Three patients failed screening at baseline and were not included in the assessment. Of the 17 patients who received atorvastatin (40 mg or 80 mg daily), 58.8% (n = 10) developed new lesions on MRI or had clinical relapses compared to 11.1% (n = 1) in the placebo group (P = .022). Signifi cant decreases were noted in the mean total cholesterol levels for the atorvastatin groups when compared to placebo but not between the atorvastatin groups. No differences were found between the 3 groups for changes in transaminases or CPK. The authors concluded that the addition of atorvastatin to interferon resulted in increased disease activity and advised that this combination should be approached with caution. 5
SAFETY
This is a limited safety profi le. Refer to package labeling for complete prescribing information (eg, Warnings/Precautions, Adverse Reactions, Drug Interactions).
In the majority of reviewed trials, atorvastatin in combination with interferon-beta therapy was similar to interferon therapy alone in regard to the frequency and types of adverse events. 4, 5, 7 In one trial, the combination therapy was more frequently associated with increased liver enzymes. (23.1% vs 5.3%; P = .02). 6
THERAPY CONSIDERATIONS
The use of adjunctive atorvastatin therapy (with interferon-beta) in the management of relapsingremitting MS has been evaluated in a limited number of controlled and noncontrolled trials demonstrating confl icting results. It has shown either moderate or no benefi t when compared to interferon therapy alone [4] [5] [6] [7] ; in one controlled trial, the combination therapy resulted in increased disease activity. 5 Two meta-analyses of statins (atorvastatin and simvastatin) examining the same trials found that there was no benefi t of statins in regard to MS relapse rates, disease progression, or change in disability scores. 8, 9 
